Kidney Transplant Rejection Clinical Trial
Official title:
The Efficacy of Plasmapheresis and Double Filtration Plasmapheresis (DFPP) in Kidney Transplant Patients With Suspected Rejection: A Retrospective Study
At present, the number of end-stage kidney disease patients is increasing. Kidney transplant
surgery is one of the treatments that give patients a better survival rate than hemodialysis
or abdominal dialysis. In Thailand, there were 5,729 kidney transplant patients or 88.9 cases
per million population in 2012. Among this number, 465 were new surgical patients or 7.2
cases per million population.
From the year 2007-2012, the survival rate of the kidney donor from living donor kidney
transplant (LDKT) was 98.5 percent and 93.3 percent at 1 and 5 years, respectively.
The most common cause of graft loss was chronic rejection by 33% of all graft loss. However,
16.1 percent were unknown reasons for graft loss.
The research question is "In patients with kidney transplantation who suspected graft
rejection" Is it true that doing plasmapheresis or DFPP is no different.
The researcher therefore conducted a comparative study. Is plasmapheresis or DFPP effective
or different side effects?
Rejection condition can be divided into 2 groups, namely cellular rejection and
antibody-mediated rejection (AbMR) by acute AbMR treatment according to the guidelines for
care for kidney transplant patients in Thailand, 2014. The introduction of a single filter
plasma (plasmapheresis) or 2 filters (DFPP) in combination with IVIG (intravenous
immunoglobulin), which may or may not be given methylprednisolone. If the patients did not
response to the treatment, Rituximab or Bortezomib was considered.
Only one previous study showed that among 29 graft rejected patients treated with
plasmapheresis, 37.9% had subsequently graft loss and the rest of them had significantly
decreasing creatinine level at 1 month follow-up. Another group of 10 graft rejected patients
treated with DFPP, 40% had subsequently graft loss. Six patients had decreasing creatinine
level at 1 month follow-up.
Both groups do not have complications or side effects from plasmapheresis or DFPP.
The researcher therefore conducted a comparative study.
Is plasmapheresis or DFPP effective or different side effects in treating post-kidney
transplant patients who suspected of graft rejection?
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04491552 -
TruGraf® Long-term Clinical Outcomes Study
|
||
Withdrawn |
NCT04560582 -
Immunosuppression Reduction in Failed Allograft Guided by cfDNA
|
||
Completed |
NCT05747274 -
SRDK0921_ Analytical Performance Study
|
||
Not yet recruiting |
NCT05482100 -
CLinical Utility of the omnigrAf® biomarkeR Panel In The Care of kidneY Transplant Recipients
|
||
Recruiting |
NCT06243289 -
Improving KIdney Transplantation With Cellular Therapy Study
|
||
Not yet recruiting |
NCT06025240 -
Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
|
||
Completed |
NCT04367610 -
Effects of A Standardized Treatment Approach on Kidney Transplant Recipients With Antibody-Mediated Rejection
|
||
Enrolling by invitation |
NCT06126380 -
Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients
|
Phase 2 | |
Terminated |
NCT05747053 -
Personalization of Immunosuppressive Treatment for Organ Transplant Recipients
|
||
Active, not recruiting |
NCT03714113 -
Donor-specific Anti-HLA Antibodies Monitoring in Kidney Transplant Recipients
|
N/A | |
Recruiting |
NCT04091984 -
The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)
|
||
Recruiting |
NCT05335538 -
TruGraf and TRAC In Pediatrics Study
|
||
Completed |
NCT03663335 -
Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients
|
Phase 2 | |
Completed |
NCT03652402 -
Precision Risk Stratification in Kidney Transplant Patients - EU-TRAIN
|
||
Recruiting |
NCT04773392 -
Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR
|
Phase 4 | |
Terminated |
NCT02974686 -
Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation
|
Phase 4 | |
Completed |
NCT03873623 -
The TOGETHER Project - Kidney
|
||
Terminated |
NCT04156204 -
Immunosuppressant Medication Dosed Daily After Kidney Transplant
|
Early Phase 1 | |
Completed |
NCT04601155 -
Transition of Renal Patients Using AlloSure Into Community Kidney Care
|
||
Completed |
NCT03874299 -
The TOGETHER Project - Kidney RNA-seq Validation
|